摘要
目的:探讨瑞舒伐他汀联合替格瑞洛治疗急性冠脉综合征的疗效及对血浆甲壳质酶蛋白40(YKL-40)、血浆α-颗粒膜蛋白(GMP-140)的作用分析。方法:选择2016年4月至2018年4月我院收治的急性冠脉综合征患者100例纳入本次研究,根据简单随机分组法分为观察组(n=52)和对照组(n=48)。对照组使用替格瑞洛治疗,观察组在对照组的基础上加用瑞舒伐他汀进行治疗。比较两组患者临床疗效、血清YKL-40、GMP-140、脑钠素(BNP)、左室射血分数(LVEF)水平及不良反应发生情况。结果:治疗后,两组患者总有效率分别为90.38%、72.92%,(P<0.05);治疗后,两组YKL-40、GMP-140水平均明显改善,且观察组显著低于对照组(P<0.05);治疗前,两组患者BNP、LVEF水平无显著性差异;治疗后,两组患者BNP、LVEF较治疗前均显著改善,且观察组患者BNP水平显著低于对照组,LVEF显著高于对照组(P<0.05);两组患者不良反应发生率分别为7.69%、29.17%(P<0.05)。结论:在急性冠脉综合征中采用瑞舒伐他汀联合替格瑞洛疗效显著,可有效改善YKL-40、GMP-140水平,值得推广应用。
Objective: To study curative efficacy of risuvastatin in combination with tigreglio in treatment of Acute coronary syndromeand its effectson Plasma chitinase protein 40(ykl-40), plasma alpha-granular membrane protein(gmp-140). Methods: 100 patients with acute coronary syndrome admitted to our hospital from April 2016 to April 2018 were selected for this study, the patients were divided into observation group(n=52) and control group(n=48) by simple random grouping. The control group was treated with tigrelol, and the observation group was treated with risuvastatin on the basis of the control group. The clinical efficacy, serum ykl-40, gmp-140, BNP, LVEF and adverse reactions were compared between the two groups. Results: After treatment, the total effective rates of the two groups were 90.38% and 72.92%, respectively(P<0.05). After treatment, the levels of ykl-40 and gmp-140 in both groups were significantly improved, and the observation group was significantly lower than the control group(P<0.05). Before treatment, there was no significant difference in BNP and LVEF levels between the two groups. After treatment, BNP and LVEF in both groups were significantly improved compared with that before treatment, and BNP level in the observation group was significantly lower than that in the control group, while LVEF was significantly higher than that in the control group(P<0.05). The incidence of adverse reactions in the two groups was 7.69% and 29.17% respectively(P<0.05). Conclusion: The use of rosuvastatin combined with tigrelol in acute coronary syndrome has significant curative effect and can effectively improve the levels of ykl-40 and gmp-140, which is worthy of promotion and application.
作者
汤宁成
杨巍
吴海义
TANG Ningcheng;YANG Wei;WU Haiyi(Rugao People's Hospital, Jiangsu Rugao 226500, China)
出处
《河北医学》
CAS
2019年第12期2061-2064,共4页
Hebei Medicine
基金
江苏省自然科学基金项目,(编号:20130186)
